Functional relationship and gene ontology classification of breast cancer biomarkers

International Journal of Biological Markers

Volumn 18, Issue 4, 2003, Pages 241-272

  Arciero, C ^a,b   Somiari, S B ^b   Shriver, C D ^a   Brzeski, H ^b   Jordan, R ^b   Hu, H ^b   Ellsworth, D L ^b   Somiari, R I ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b WINDBER RESEARCH INSTITUTE   (United States)

Author keywords

Biochemical function; Biological markers; Breast cancer prognosis; Gene ontology

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CATHEPSIN; CYCLIN D1; CYTOKERATIN 19; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MATRIX METALLOPROTEINASE; MUCIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27; PROTEIN P53; TUMOR MARKER; UROKINASE; VASCULOTROPIN;

BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE FUNCTION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENOMICS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN GENOME; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; PREDICTION; PROGNOSIS; PROTEOMICS; RAT; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 1242342158     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1352     Document Type: Review

References (336)

1. American Cancer Society. How many people get breast cancer? 2003 http://www.cancer.org/docroot/CRI/content/ CRI_2_2_1X_How_many_people_get_breast_cancer-5.asp?sitearea
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
3. Leinster SJ, Downey H, Gibbs TJ. Shared care for breast disease. Oxford, UK: Isis Medical Media Ltd., 2000; 125.
4. Rubinstein WS. The genetics of breast cancer. In: Vogel VG, ed. Management of patients at high risk for breast cancer. Malden, MA: Blackwell Science, 2001.
5. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000; 36: 170-6. F<<>>⌋frt Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000; 36: 170-6.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
7. Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 1990; 354A: 209-21.
8. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-9.
9. Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis PN. Co-expression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 1994; 120: 737-42.
10. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Path 1997; 151: 761-8.
11. van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37 (Suppl 1): 11-7.
12. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001; 37 (Suppl 1): 3-10.
13. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
14. Collins FS, Morgan M, Patrinos A. The human genome project: lessons from large-scale biology. Science 2003; 5617: 286-90.
15. Alberti S. Preface: Workshop "Emerging molecular markers in oncology: Focused therapy, indicators of response, chemoprevention". Int J Biol Markers 2003; 18: 35.
16. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3: 243-52.
17. Lippman ME, Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980; 46 (12 Suppl): 2829-34.
18. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997; 272: 19858-62.
19. Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J. Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 1998; 55 (Suppl 1): 5-10.
20. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue-distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
21. Clark GM, Wenger CR, Beardslee S, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993; 71 (6 Suppl): 2157-62.
22. Gottardi O, Baiocchi C, Ferrari M, et al. Correlation between histochemically assessed hormonal receptor content and clinical course in breast cancer. Presentation of 1,005 cases. Oncology 1991; 48: 221-5.
23. Pichon MF, Milgrom E. Oestrogen receptor negative-progesterone receptor-positive phenotype in 1,211 breast tumours. Br J Cancer 1992; 65: 895-7.
24. Tsangaris TN, Knox SM, Cheek JH. Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma. Cancer 1992; 69: 984-7.
25. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project protocol B 06. J Clin Oncol 1988; 6: 1076-87.
26. Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol 1992; 19: 244-53.
27. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983; 1: 227-41.
28. Hilf R, Feldstein ML, Gibson SL, Savlov ED. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 1980; 45: 1993-2000.
29. Raemaekers JM, Beex LV, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW. Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: The role of adjuvant chemotherapy. Breast Cancer Res Treat 1987; 9: 191-9.
30. Andersen J. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. Acta Oncol 1992; 31: 611-27.
31. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1284-91.
32. Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker RR. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 70-4.
33. Stuart NS, Philip P, Harris AL, et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992; 66: 833-9.
34. Lin VC, Ng EH, Aw SE, et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999; 5: 395-403.
35. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, Bay BH. Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol 2000; 14: 348-58.
36. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelénat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998; 49: 219-25.
37. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999; 79: 1564-71.
38. Mai GF, Zheng H, Luo RC, Liao WJ, Zhang LS, He XB. Association of progesterone receptor and HER2 expressions with the survival time of patients with breast cancer. Di Yi Jun Yi Da Xue Xue Bao 2003; 4: 372-4.
39. Pinto AE, André S, Mendonça E, Silva G, Soares J. Overall survival in advanced breast cancer: Relevance of progesterone receptor expression and DNA ploidy in fine-needle aspirates of 392 patients. Int J Biol Markers 2003; 18: 7-12.
40. Schneider J, Pollan M, Tejerina A, Sanchez J, Lucas AR. Accumulation of uPA-PAI-1 complexes inside the tumor cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer 2003; 88: 96-101.
41. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9.
42. Müller V, Thomssen C, Karakas C, et al. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 2003; 18: 13-20.
43. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-4.
44. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992; 7: 1027-32.
45. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992; 7: 1859-66.
46. Rob H, Pippin JA, Green DW, et al. HER2/neu anti-sense targeting of human breast carcinoma. Oncogene 2000; 19: 6138-43.
47. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999; 26 (4 Suppl 12): 78-83.
48. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunopheno-type and gene amplification. J Clin Oncol 2001; 19: 2587-95.
49. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
50. Piccart-Gebhart MJ. Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs 2001; 12 (Suppl 4): S27-33.
51. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 5: 2894-904.
52. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 1998; 90: 1320-1.
53. Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol 2000; 11: 1343-7.
54. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217-25.
55. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
56. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003; 97: 1758-65.
57. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52: 79-98.
58. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
59. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993; 4: 897-906.
60. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
61. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57.
62. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-10.
63. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
64. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
65. Ellis PE, Fong LF, Rolfe KJ, et al. The role of p53 and Ki67 in Paget's disease of the vulva and the breast. Gynecol Oncol 2002; 86: 150-6.
66. Elledge RM, Green S, Howes L, et al. BCL-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997; 15: 1916-22.
67. Stal O, Stenmark Askmalm M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995; 34: 767-70.
68. Elledge RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87: 1254-6.
69. Degeorges A, de Roquancourt A, Extra JM, et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 1998; 47: 47-55.
70. Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002; 100: 290-6.
71. Guerra E, Vacca G, Palombo B, Alberti S. Prognostic value of mutations IN TP53 and RAS gene in breast cancer. Int J Biol Markers 2003; 18: 49-53.
72. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52: 1-15.
73. Casey G, Smith R, McGillivray D, Peters G, Dickson C. Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol 1986; 6: 502-10.
74. Lammie GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439-44.
75. Gillett C, Fantl V, Smith R, et al. Amplification and over-expression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-7.
76. Buckley MF, Sweeney KJ, Hamilton JA, et al. Cyclin A expression in normal and transformed alveolar epithelial cells. Oncogene 1993; 8: 2127-33.
77. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996; 2: 1177-84.
78. Barbareschi M, Pelosio P, Caffo O, et al. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer 1997; 74: 171-4.
79. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002; 86: 580-6.
80. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996; 56: 3168-72.
81. Nahta R, Inglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002; 62: 2267-71.
82. Pusch O, Soucek T, Wawra E, Hengstschlager-Ottnad E, Bernaschek G, Hengstschlager M. Specific transformation abolishes cyclin D1 fluctuation throughout the cell cycle. FEBS Lett 1996; 385: 143-8.
83. Atadja P, Wong H, Veillete C, Riabowol K. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 1995; 217: 205-16.
84. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9: 2364-72.
85. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82: 621-30.
86. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11: 885-91.
87. Michalides R, Hageman P, van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73: 728-34.
88. Pelosio P, Barbareschi M, Bonoldi E, et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 1996; 7: 695-703.
89. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996; 69: 92-9.
90. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997; 14: 295-304.
91. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Over-expression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995; 1: 1257-60.
92. Van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Path 1997; 150: 705-11.
93. Gillett CE, Barnes DM. Demystified... cell cycle. Mol Pathol 1998; 51: 310-6.
94. Sutherland RL, Pratt OWJ, Alle KM, et al. Cyclin dependent kinases as downstream targets of estrogen action: potential prognostic indicators and therapeutic targets. Endocr Relat Cancer 1997; 4: 357-70.
95. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4, Mol Cell Biol 1997; 17: 5338-47.
96. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of anti-estrogens. Clin Cancer Res 1997; 3: 849-54.
97. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002; 98: 415-8.
98. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
99. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-5.
100. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive carcinomas. Cancer Res 1997; 57: 1259-63.
101. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 6380-5.
102. Kellner U, Rudolph P, Parwaresch R. Human DNA-topoisomerases - diagnostic and therapeutic implications for cancer. Onkologie 2000; 23: 424-30.
103. Champoux JJ. Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3′-terminus of the nicked DNA. J Mol Biol 1978; 118: 441-6.
104. Maxwell A, Gellert M. Mechanistic aspects of DNA topoisomerases. Adv Protein Chem 1986; 38: 69-107.
105. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 1989; 41: 223-41.
106. Miller KG, Liu LF, Englund PT. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 1981; 256: 9334-9.
107. Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22 Proc Natl Acad Sci USA 1988; 85: 7177-81.
108. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-14.
109. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Path 1995; 146: 1302-8.
110. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994; 34: 191-218.
111. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 1994; 77: 609-16.
112. Isaacs RJ, Davies SL, Wells NJ, Harris AL. Topoisomerase II alpha and beta as therapy targets in breast cancer. Anti-cancer Drugs 1995; 6: 195-211.
113. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998; 1400: 121-37.
114. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17: 389-97.
115. Nakopoulo L, Katsarou S, Giannopoulou I, et al. Correlation of TIMP-2 with proliferative activity and patients' survival in breast cancer. Mod Path 2002; 15: 26-34.
116. Villman K, Stahl E, Liljegren G, Tidefelt U, Karlsson MG. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 2002; 15: 486-91.
117. Shpitz B, Bomstein Y, Zehavi T, et al. Topoisomerase II alpha expression in ductal carcinoma in situ of the breast: A preliminary study. Hum Pathol 2000; 31: 1249-54.
118. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997; 28: 1180-8.
119. Sampson SA, Kreipe H, Gillett CE, et al. KiS1, a novel monoclonal antibody that recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 1992; 168: 179-85.
120. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-8.
121. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase II alpha expression in breast cancer: Correlation with outcome variables. Mod Pathol 2000; 13: 542-7.
122. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiol 2000; 68: 137-43.
123. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with Erb-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Path 2000; 156: 839-47.
124. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, Chromosomes Cancer 1999; 26: 142-50.
125. Jarvinen TA, Holli K, Kuukasjarvi T, Isola J. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-73.
126. Eder JP, Chan VT, Ng SW, et al. DNA topoismoerase II alpha expression is associated with alkylating agent resistance. Cancer Res 1995; 55: 6109-16.
127. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-16.
128. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-7.
129. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res 2001; 92: 1133-7.
130. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 1999; 12: 1094-100.
131. Roymans D, Vissenberg K, De Jonghe C, et al. Identification of the tumor metastasis suppressor Nm23-H1/Nm23-R1 as a constituent of the centrosome. Exp Cell Res 2001; 262: 145-53.
132. Postel EH, Abramczyk BM, Levit MN, Kyin S. Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function. Proc Natl Acad Sci USA 2000; 97: 14194-9.
133. Wallet V, Mutzel R, Troll H, et al. Dictyostelium nucleoside diphosphate kinase highly homologous to Nm23 and Awd proteins involved in mammalian tumor metastasis and Drosophila development. J Natl Cancer Inst 1990; 82: 1199-202.
134. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-4.
135. Caligo MA, Cipollini G, Cope Di Valromita A, Bistocchi M, Bevilacqua G. Decreasing expression of NM23 gene in metastatic murine mammary tumors of viral etiology (MMTV). Anticancer Res 1992; 12: 969-73.
136. Su ZZ, Austin N, Zimmer SG, Fisher PB. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993; 8: 1211-9.
137. Lakshmi MS, Parker C, Sherbet GV. Metastasis associated MTS1 and NM23 genes affect tubulin polymerisation in B16 melanomas: a possible mechanism of their regulation of metastatic behaviour of tumours. Anticancer Res 1993; 13: 299-303.
138. MacDonald NJ, DeLaRosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Int J Cancer 1995; 31A: 1096-100.
139. Mao H, Liu H, Fu X, Fang Z, Abrams J, Worsham MJ. Loss of nm23 expression predicts distal metastasis and poorer survival for breast cancer. Int J Oncol 2001; 18: 587-91.
140. Chen SL, Wu YS, Shieh HY, Yen CC, Shen JJ, Lin KH. P53 is a regulator of the metastasis suppressor gene Nm23-H1. Mol Carcinog 2003; 36: 204-14.
141. Baba H, Urano T, Okada K, et al. Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res 1995; 55: 1977-81.
142. Fukuda M, Ishii A, Yasutomo Y, et al. Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary-adenocarcinoma cells. Int J Cancer 1996; 65: 531-7.
143. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993; 8: 2325-33.
144. Kantor JD, McCormick B, Steeg PS, Zetter BR. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res 1993; 53: 1971-3.
145. MacDonald NJ, Freije JM, Stracke ML, Manrow RE, Steeg PS. Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem 1996; 271: 25107-16.
146. Sauer T, Furu I, Beraki K, Jebsen PW, Ormerod E, Naess O. NM23 protein expression in fine-needle aspirates from breast carcinoma: Inverse correlation with cytologic grading, lymph node status and ploidy. Cancer 1998; 84: 109-14.
147. Niu Y, Fu X, Lv A, Fan Y, Wang Y. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 2002; 98: 754-60.
148. Hartsough MT, Steeg PS. Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am J Hum Genet 1998; 63: 6-10.
149. Forus A, D'Angelo A, Henriksen J, et al. Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering nm23-H1 activity. Oncogene 2001; 20: 6881-90.
150. Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997; 65: 22-7.
151. Brown PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998; 52: 125-36.
152. Opdenakker G, Van Damme J. Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 1992; 13: 463-4.
153. Ponton A, Coulombe B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51: 2138-43.
154. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101.
155. Rha SY, Yang WI, Kim JH, et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 1998; 5: 875-9.
156. Hanemaaijer R, Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000; 86: 204-7.
157. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140-6.
158. MacDougall JR, Matrisian LM. Matrix metalloproteinases in the pathogenesis of breast cancer. In: Bowcock AM, ed. Breast cancer: Molecular genetics, pathogenesis, and therapeutics. Totowa, NJ: Humana Press Inc, 1998.
159. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
160. Fingleton B, Matrisian LM. Metalloproteinases in cancer. In: Clendeninn NJ, Appelt K, eds. Cancer drug discovery and development: Matrix metalloproteinase inhibitors in cancer therapy. Totowa, NJ: Humana Press Inc, 1998; 85-112.
161. Halaka AN, Bunning RA, Bird CC, Gibson M, Reynolds JJ. Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg 1983; 59: 461-6.
162. Hicks NJ, Ward RV, Reynolds JJ. A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumour cell lines. Int J Cancer 1984; 33: 835-44.
163. Welch DR, Fabra M, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990; 87: 7678-82.
164. Kitson RP, Appasamy PM, Nannmark U, Albertsson P, Gabauer MK, Goldfarb RH. Matrix metalloproteinases produced by rat IL-2-activated NK cells. J Immunol 1998; 160: 4248-53.
165. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an upregulation of VEGF expression. FASEB J 2002; 16: 555-64.
166. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Path 1990; 136: 585-92.
167. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996; 73: 1401-8.
168. Polette M, Clavel C, Cockett M, Girod de Bentzmann S, Murphy G, Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993; 13: 31-7.
169. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin super-family. Cancer Res 1995; 55: 434-9.
170. Himelstein BF, Canete-Soler R, Bernhard EJ, Muschel RJ. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 1994; 107: 477-86.
171. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of MMP2 in patients with breast cancer. Cancer Lett 2001; 173: 79-82.
172. Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111.
173. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-3.
174. Frandsen TL, Holst-Hansen C, Nielsen BS, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001; 61: 532-7.
175. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract 1995; 191: 403-9.
176. Pedersen AN, Christensen IJ, Stephens RW, et al. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60: 6927-34.
177. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-30.
178. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-7.
179. Pacheco MM, Nishimoto IN, Mourao-Neto M, Mantovani EB, Brentani MM. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 2001; 16: 62-8.
180. Albo D, Berger DH, Rothman VL, Tuszynski GP. Role of urokinase plasminogen activator receptor in thrombospondin-1 mediated tumor cell invasion. J Surg Res 1999; 82: 331-8.
181. Abaza MS, Narayan RK, Atassi MZ. Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro. Tumour Biol 1998; 19: 229-37.
182. Fersis N, Kaufmann M, Kramer MD, Wittmann G, Wallwiener D, Bastert G. Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma. Geburtshilfe Frauenheilkd 1996; 56: 28-34.
183. Sliva D, English D, Lyons D, Floyd FP. Protein kinase C induces motility of breast cancers by upregulating secretion of uPA through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 2002; 290: 552-7.
184. Sieuwerts AM, Klijn JG, Henzen-Logmans SC, Foekens JA. Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat 1999; 55: 9-20.
185. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulationof urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase. Cancer Res 2001; 61: 1367-74.
186. Evans DM, Sloan-Stakleff KD. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis 1998-99; 18: 252-60.
187. Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000; 83: 298-306.
188. Xing RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. Int J Cancer 1999; 81: 443-50.
189. Harbeck N, Alt U, Berger U, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64.
190. Janicke F, Prechtl A, Thomssen C, el al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
191. Billgren AM, Rutqvist LE, Johansson H, Hagerstrom T, Skoog L. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. Eur J Cancer 2000; 36: 1374-80.
192. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
193. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
194. Ishikawa N, Endo Y, Sasaki T. Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Jpn J Cancer Res 1996; 87: 480-7.
195. Evans DM, Lin PL. Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 1995; 61: 692-6.
196. Duggan C, Kennedy S, Kramer MD, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 1997; 76: 622-7.
197. Schrohl AS, Pedersen AN, Jensen V, et al. Tumour tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in breast cancer. Mol Cell Proteomics 2003, 2: 164-72.
198. Riley LB, Lange MK, Browne RJ, et al. Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Res Treat 2000; 60: 173-9.
199. Tandon AK, Clark GM, Chamness GC, McGuire WL. Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer. Cancer Res 1990; 50: 3317-21.
200. Gonzalez-Vela MC, Garijo MF, Fernandez F, Buelta L, Val-Bernal JF. Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma. Histopath 1999; 34: 35-42.
201. Wang F, Samudio I, Safe S. Transcriptional activation of cathepsin D gene expression by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol Cell Endocrinol 2001; 172: 91-103.
202. Tetu B, Brisson J, Lapointe H, Wang CS, Bernard P, Blanchette C. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases. Breast Cancer Res Treat 1999; 55: 137-47.
203. Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res 1992; 12: 235-40.
204. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990; 16: 3-13.
205. Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000; 291: 157-70.
206. Vetvicka V, Vetvickova J, Hilgert I, Voburka Z, Fusek M. Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int J Cancer 1997; 73: 403-9.
207. Gaci Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Metaye T. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol 2001; 18: 793-800.
208. Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius VM, Blomqvist C. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer 1999; 80: 167-74.
209. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47: 9-16.
210. Solomayer FF, Diel IJ, Meyberg GC, et al. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat 1998; 49: 145-54.
211. Foekens JA, Look MP, Bolt-de Vries J, et al. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300-7.
212. Lah TT, Cercek M, Blejec A, et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin Cancer Res 2000; 6: 578-84.
213. Xing R, Addington AK, Mason RW. Quantification of cathepsins B and L in cells. Biochem J 1998; 332 (Pt 2): 499-505.
214. Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ. High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers 1998; 13: 139-44.
215. Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Path 1998; 153: 11-5.
216. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
217. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-47.
218. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-6.
219. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling in breast cancer. Cell Growth Differ 2001; 12: 129-35.
220. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
221. Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264: 20017-24.
222. Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 1999; 53: 161-6.
223. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; (5 Suppl 1): 37-44.
224. Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001; 15: 140-4.
225. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) up-regulates bcl-2 and inhibits apoptosis in human and murine mammary adenocarinoma cells. Br J Cancer 2001; 85: 273-8.
226. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000; 192: 150-8.
227. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28 (5 Suppl 16): 27-32.
228. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Boucher-Hays DJ. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997; 4: 621-7.
229. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998; 5: 673-7.
230. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VFGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311-5.
231. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-5.
232. Hajitou A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001; 61: 3450-7.
233. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-8.
234. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19: 4203-14.
235. Im SA, Kim JS, Gomez-Manzano C, et al. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 2001; 84: 1252-7.
236. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 1996; 271: 19310-7.
237. Gunningham SP, Currie MJ, Han C, et al. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol 2001; 193: 325-32.
238. Kurebayashi J, Otsuki T, Kunisue H, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999; 90: 977-81.
239. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829-37.
240. Salven P, Lymboussaki A, Heikkial P, et al. Vascular endothelial growth facotrs VEGF-B and VEGF-C are expressed in human tumors. Am J Path 1998; 153: 103-8.
241. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-90.
242. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001; 66: 159-64.
243. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
244. Nakamura Y, Yasuaka H, Tsujimoto M, et al. Clinicopathological significance of vascular endothelial growth factor-c in breast carcinoma with long term follow-up. Mod Pathol 2003; 16: 309-14.
245. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VFGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-53.
246. Kahn HJ, Yang LY, Blondal J, et al. RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. Breast Cancer Res Treat 2000; 60: 143-51.
247. Aerts J, Wyendaele W, Paridaens R, et al. A real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 2001; 12: 439-61.
248. Berois N, Varangot M, Aizen B, et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer 2000; 36: 717-23.
249. Bartek J, Taylor-Papadimitriou J, Miller N, Millis R. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer 1985; 36: 299-306.
250. Rose MG, Burtness BA, Crouch JY, Marsh JC, Reiss M, Howe JG. Detection of circulating breast cancer cells by reverse transcription-polymerase chain reaction (RT-PCR) for cytokeratin 19 (CK19) in patients with breast cancer. Proc Annu Meet Soc Clin Oncol 1997; 16: A662.
251. Zhong XY, Kaul S, Diel I, Eichler A, Bastert G. Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products. J Cancer Res Clin Oncol 1999; 125: 286-91.
252. Silva JM, Dominguez G, Silva J, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 2001; 7: 2821-5.
253. Yang DC, Head JF, Jiang XF, Elliott RL. Expression of cytokeratin 19 mRNA is associated with differentiation of human breast tumors. Proc Am Soc Clin Oncology 1998; abstract 2198.
254. Fleming TP, Watson MA. Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci 2000; 923: 78-89.
255. Colpitts TL, Billing-Medel P, Friedman P, et al. Mammaglobin is found in breast tissue as a complex with bu101. Biochemistry 2001; 40: 11048-59.
256. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59: 3028-31.
257. Kataoka A, Mori M, Sadanaga N, et al. RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol 2000; 16: 1147-52.
258. Ooka M, Sakita I, Fujiwara Y, et al. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep 2000; 7: 561-6.
259. Grunewald K, Haun M, Urbanek M, et al. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19 Lab Invest 2000; 80: 1071-7.
260. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17: 2015-9.
261. Ooka M, Tamaki Y, Sakita I, et al. Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Res Treat 2001; 67: 169-75.
262. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D. Detection of mammaglobin mRNA as a marker for circulating tumor cells in breast carcinoma. Acta Med Austriaca 2000; 27: 13-5.
263. Houghton RL, Dillon DC, Molesh DA, et al. Transcriptional complementarity in breast cancer: Application to detection of circulating tumor cells. Mol Diagn 2001; 6: 79-91.
264. Scibetta AG, Albanese I, Morris J, et al. Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways. DNA Cell Biol 2001; 20: 265-74.
265. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001; 91: 1973-82.
266. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129: 255-65.
267. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 2000; 15: 330-3.
268. Gion M, Mione R, Leon AE, et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001; 37: 355-63.
269. Briasoulis E, Andreopoulou E, Tolis CF, et al. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001; 91: 909-17.
270. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T. Serum CA15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988; 58: 213-5.
271. Miserez AR, Gunes I, Muller-Brand J, Walther E, Fridrich R, Macke H. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. Eur J Cancer 1991; 27: 126-31.
272. Barak V, Carlin D, Sulkes A, Treves A, Biran S. CA15-3 serum levels in breast cancer and other malignancies-correlation with clinical course. Isr J Med Sci 1988; 24: 623-7.
273. McLaughlin R, McGrath J, Grimes H, Given HE. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15: 340-2.
274. Wojtacki J, Dziewulska-Bokiniec A, Skokowski J, Ciesielski D. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Neoplasma 1994; 41: 213-6.
275. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991; 200: 81-93.
276. Canizares F, Sola J, Perez M, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001; 22: 273-81.
277. Hayes DF, Zurawski VR Jr, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542-50.
278. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989; 4: 207-14.
279. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13: 123-33.
280. Einarsson R, Lindman H, Bergh J. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Anticancer Res 2000; 20: 5089-93.
281. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor CA 15.3 and stage are the most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002; 76: 95-102.
282. Hou MF, Chen YL, Tseng TF, et al. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 1999; 15: 520-8.
283. Lufter D, Richter A, Gunther S, et al. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer. Anti-cancer Res 2000; 20: 5099-105.
284. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al. Anti body-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93: 97-106.
285. Hall JM, Friedman L, Guenther C, et al. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet 1992; 50: 1235-42.
286. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13 Science 1994; 265: 2088-90.
287. Yang X, Lippman ME. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 1999; 54: 1-10.
288. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137: 678-87.
289. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 1998; 95: 2302-6.
290. Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997; 94: 5605-10.
291. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Bordy LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 upon DNA damage. Nat Genet 2002; 30: 285-9.
292. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-50.
293. Rao VN, Shao N, Ahmad M, Reddy ES. Anti-sense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996; 12: 523-8.
294. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354-6.
295. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 2002; 4: 9-13.
296. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992; 2: 128-31.
297. Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 1998; 17: 3169-76.
298. Ishitobi M, Miyoshi Y, Ando A, et al. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin Cancer Res 2003; 9: 1376-80.
299. Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7: 103-7.
300. Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelénat H. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol 1990; 94: 681-6.
301. Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152: 287-95.
302. Weidner N, Moore DH II, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994; 25: 337-42.
303. D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol 1991; 4: 239-46.
304. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002; 15: 1044-50.
305. Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. Breast J 2002; 8: 376-81.
306. Dervan PA, Gilmartin LG, Loftus BM, Carney DN. Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol 1989; 92: 401-7.
307. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59: 943-7.
308. Midulla C, Pisani T, De lorio P, et al. Cytological analysis and immunocytochemical expression of Ki67 and Bcl-2 in breast proliferative lesions. Anticancer Res 2002; 22: 1341-5.
309. Charpin C, Andrac L, Lavaut MN, et al. Image cytometry of aneuploidy, growth fraction (MoAb Ki-67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas. Anal Cell Pathol 1990; 2: 357-71.
310. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627-33.
311. Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995; 345: 1181-2.
312. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992; 28: 681-3.
313. Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002; 100: 290-6.
314. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2002; 39: 462-8.
315. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-12.
316. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003; 9 (1 Pt 2): 502S-10S.
317. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15: 853-61.
318. Silvestrini R, Benini E, Veneroni S, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-10.
319. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999; 6: 29-40.
320. Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep 1998; 5: 1211-6.
321. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-98.
322. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999; 6: 61-8.
323. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
324. Daidone MG, Veneroni S, Benini E, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 1999; 84: 580-6.
325. Daidone MG, Luisi A, Martelli G, et al. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000; 82: 270-7.
326. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet 2000; 25: 25-9.
327. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-33.
328. Makris A, Allred DC, Powles TJ, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997; 44: 65-74.
329. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; 5 (Suppl 1): 37-44.
330. Biroccio A, Candiloro A, Mottolese M, et al. Bcl-2 over-expression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 2000; 14: 652-60.
331. Zolota V, Gerokosta A, Melachrinou M, Kominea A, Aletra C, Scopa CD. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast. Anticancer Res 1999; 19: 32 69-74.
332. Bottini A, Berruti A, Bersiga A, et al. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 2002; 8: 1816-21.
333. Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA. Global functional profiling of gene expression. Genomics 2003, 81: 98-104.
334. Van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
335. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
336. Bernard-Gallon DJ, Dechelotte PJ, Le Corre L, et al. Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias. Anticancer Res 2003; 23: 661-7.